undefined

Matthew Schrag

Neuroscientist at Vanderbilt University who discovered potential fraud in Alzheimer's research, leading to widespread media coverage.

Top 3 podcasts with Matthew Schrag

Ranked by the Snipd community
undefined
Aug 15, 2022 • 1h 36min

A Deep Dive Into Alzheimer's and Disturbing New Scientific Findings, with Dr. Dale Bredesen, Dr. Matthew Schrag, and Charles Piller | Ep. 373

Join Dr. Matthew Schrag, a neuroscientist known for exposing fraud in Alzheimer's research, alongside investigative journalist Charles Piller, as they delve into the ethics of scientific integrity. Dr. Dale Bredesen, renowned for his work on Alzheimer's, discusses alternative treatment approaches amid controversy over drug efficacy and manipulated data. They tackle the amyloid hypothesis, the significance of lifestyle factors like diet, and the need for transparency in research. Plus, discover insights on genetic risk factors and proactive measures to enhance brain health.
undefined
Feb 8, 2025 • 38min

Spending on the Right Things: Future of Cancer, Alzheimer's, Global Debt Cycles

Albert Bourla, CEO of Pfizer, discusses the company's focus on innovative cancer treatments and the role of AI in drug development. Ray Dalio shares insights on rising global debt, urging smart management for economic stability. Matthew Schrag, a neurologist at Vanderbilt, raises red flags about research integrity in Alzheimer's treatments, stressing the urgent need for accountability in scientific studies. Together, they explore the intersection of healthcare innovation and economic challenges, emphasizing the importance of prioritizing effective therapies.
undefined
Nov 15, 2024 • 15min

Misconduct and the future of neurodegenerative disease research

Matthew Schrag, a prominent neuroscientist at Vanderbilt University Medical Center, sheds light on a major research misconduct scandal involving Eliezer Masliah, whose manipulated imaging has tainted the credibility of neurodegenerative disease research. Schrag discusses the implications for Alzheimer’s and Parkinson’s drug development and highlights ongoing issues with treatments, including concerns over antibody efficacy and the need for innovative strategies. He stresses the critical importance of maintaining scientific integrity to ensure patient care and progress in this crucial field.